Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasm, Residual × Midazolam × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pain, Intractable 1 Neoplasms 1 Neoplasm, Residual 1 Nausea 1 Leukemia, Myeloid, Acute 1 Dyspnea 1 Delirium 1 Death 1

Interventions

siremadlin 1 selinexor 1 posaconazole 1 midostaurin 1 fludarabine 1 durvalumab 1 blinatumomab 1 avelumab 1 Radiosurgery 1 Midazolam 1 Lenalidomide 1 Idarubicin 1 Dexamethasone 1 Daunorubicin 1 Cytarabine 1 Cyclophosphamide 1 Calcium Dobesilate 1 Azacitidine 1 Anthracyclines 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡